Heart Failure
15 videos · last 6 months shuffled daily, then older videos newest first
▶
11:25 HELIOS-B: Vutrisiran With and Without Tafamidis in ATTR-CM
Yasuhiro Hamatani, MD, PhD, discusses a HELIOS-B analysis in transthyretin amyloid cardiomyopathy finding vutrisiran's effects on mortality and cardiovascular events consistent in direction with or without baseline tafamidis, for JACC.
▶
3:43 Dr. Barry Borlaug and Dr. C. Michael Gibson Discuss: RAPID-HF
Dr. Barry Borlaug and Dr. C. Michael Gibson discuss RAPID-HF, a randomized trial of atrial pacing in heart failure with preserved ejection fraction.
▶
14:34 ARIES HM3: Avoiding Aspirin With LVADs
Dr. Mandeep Mehra and Dr. C. Michael Gibson discuss the primary results of ARIES HM3, an international, double-blind, placebo-controlled trial of avoiding aspirin in advanced heart failure patients with left ventricular assist devices, for Snackable Health.
▶
1:06:09 Affinia BAG3 DCM - UPBEAT Clinical Trial Webinar Recording 6.10.26
The Genetic Cardiomyopathy Awareness Consortium on AFTX-201, an investigational one-time gene therapy for dilated cardiomyopathy caused by BAG3 mutations, and the UPBEAT trial.
▶
32:37 Patient-Reported Endpoints in Heart Failure Trials
CardioPod: Heart of the Matter examines the Kansas City Cardiomyopathy Questionnaire and the opportunities and challenges of using patient-reported outcomes as endpoints in heart failure clinical trials.
▶
12:08 Short vs Full KCCQ Questionnaire in Heart Failure
Yasuhiro Hamatani, MD, PhD, discusses his JACC study using TOPCAT, PARAGON-HF, DELIVER and FINEARTS-HF data to test whether the 12-item Kansas City Cardiomyopathy Questionnaire can stand in for the FDA-qualified 23-item version in heart failure.
▶
32:56 Derisking Phase II Clinical Trials in Heart Failure
Scott D. Solomon, Ellis Unger, James Wittes, Michael Felker, Ben Saville, Douglas Mann and Fady Malik discuss how to design Phase II heart failure trials that generate meaningful data and improve the chances of success in later-stage studies, on CardioPod.
▶
47:31 ESC 2026 Trials to Watch with Prof Van Mieghem & Dr Bertrand
Prof Nicolas Van Mieghem and Dr Philippe Bertrand discuss the Hot Line trials at ESC Congress 2026 they believe could most influence cardiovascular practice, from ACACIA-HCM and STAREE to LIBREXIA ACS and TRIC-I-HF.
▶
2:45 ATTRibute-CM: Acoramidis Survival Over 54 Months
Kevin Alexander, MD, and C. Michael Gibson, MD, discuss interim findings from ATTRibute-CM and its open-label extension on survival with acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy, including p.V142I.
▶
31:39 Heart Failure Shunt Trial: Alt Flow
The University of Kansas Health System's All Things Heart discusses a clinical trial testing whether shunts placed inside the heart can help blood flow properly and reduce pressure in heart failure.
▶
15:56 CardiAMP Heart Failure Trial Coordinators' Video
BioCardia on coordinator perspectives on the CardiAMP heart failure trial and patient recruitment.
▶
15:46 The Future of Heart Failure Clinical Trials in Canada
Dr. Justin Ezekowitz, Director of Cardiovascular Research and Co-Director of the Canadian VIGOUR Centre at the University of Alberta, discusses the future of heart failure clinical trials in Canada at the 2024 Ted Rogers Centre Heart Failure Symposium.
▶
26:33 Recurrent Events vs Time to First Event in Trials
John McMurray, Stuart Pocock, Marc Pfeffer, Brian Claggett, L.J. Wei and others discuss analysing recurrent events versus time to first event in cardiovascular and heart failure clinical trials, on CardioPod: Heart of the Matter.
▶
3:42 05482-A (MKT) CardiAMP Heart Failure Trial Video
Dr. Amish Raval of the University of Wisconsin - Madison talks about the CardiAMP cell therapy and the pivotal phase III CardiAMP Heart Failure Trial.
▶
1:12:11 Tenaya Therapeutics' Chief Medical Officer on Gene Therapy
Dr. Whit Tingley, Chief Medical Officer at Tenaya Therapeutics, gives an overview of gene therapy and an update on Tenaya's trials, followed by a Q&A.